Torray LLC Myovant Sciences Ltd. Transaction History

Torray LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 04, 2022	SELL	$11.6 - $20.44 $28,420 - $50,078	-2,450 Reduced 3.0%	79,171 $1.42 Million
Q2 2022 Aug 03, 2022	BUY	$7.78 - $14.69 $13,638 - $25,751	1,753 Added 2.19%	81,621 $1.02 Million
Q1 2022 May 03, 2022	BUY	$11.38 - $16.4 $283,236 - $408,179	24,889 Added 45.27%	79,868 $1.06 Million
Q4 2021 Feb 04, 2022	SELL	$14.31 - $23.87 $276,555 - $461,311	-19,326 Reduced 26.01%	54,979 $856,000
Q3 2021 Nov 02, 2021	BUY	$18.94 - $26.99 $11,382 - $16,220	601 Added 0.82%	74,305 $1.67 Million
Q2 2021 Aug 03, 2021	BUY	$17.07 - $24.56 $178,603 - $256,971	10,463 Added 16.54%	73,704 $1.68 Million
Q1 2021 May 03, 2021	BUY	$20.46 - $25.18 $27,743 - $34,144	1,356 Added 2.19%	63,241 $1.3 Million
Q4 2020 Feb 03, 2021	BUY	$13.8 - $27.62 $8,597 - $17,207	623 Added 1.02%	61,885 $1.71 Million
Q3 2020 Nov 02, 2020	BUY	$14.05 - $22.6 $129,512 - $208,326	9,218 Added 17.71%	61,262 $861,000
Q2 2020 Aug 03, 2020	BUY	$7.34 - $20.84 $382,002 - $1.08 Million	52,044 New	52,044 $1.07 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Torray LLC, based on Form 13F filings with the SEC.

Stay updated on Torray LLC with notifications on news.